Paediatric acute haemorrhagic leukoencephalitis
- 1 Pediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
- 2 Radiodiagnosis, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
- Correspondence to Dr Daisy Khera; pushpinderdaisy@gmail.com
Abstract
We report a case of a preschool age girl, previously healthy, referred to our hospital on ventilatory support with a history of vomiting, headache, and rapid neurological worsening within 24 hours in the form of seizures, encephalopathy and loss of consciousness. On presentation, she was deeply comatose with dilated non-reactive pupils, absent brainstem reflexes and flaccid quadriplegia. Diagnosis of acute haemorrhagic leukoencephalitis was considered based on laboratory and neuroimaging findings. MRI of the brain showed fluffy white matter hyperintensities and microhaemorrhages in bilateral cerebral hemispheres and thalami. Aggressive treatment with methylprednisolone, plasmapheresis and intravenous immunoglobulin showed dramatic improvement with no neurological sequelae. Our case is unique in a way that despite the hyperacute onset and rapid deterioration, with a fulminant course in the intensive care unit, the child recovered dramatically with aggressive management.
Background
Acute haemorrhagic leukoencephalitis (AHLE), also known as Weston Hurst syndrome, is a rare hyperacute variant of acute disseminated encephalomyelitis (ADEM) characterised by severe, rapidly progressive clinical illness and diffuse haemorrhagic necrosis of white matter.1 ADEM and AHLE represent two clinical variants of demyelinating disease spectrum with the former being more common in children with favourable outcomes and the latter being rare, and more prevalent in young adults with the fulminant course and high mortality. The definitive aetiology of AHLE is not well defined but antecedent upper respiratory tract infections support the hypothesis of an autoimmune process based on molecular mimicry.2
Since Hurst described the first case in 1941, the total number of reported cases has remained under 100 in 75 years, with most mentioning very high mortality.3 4 The ideal management of this condition is debatable, but aggressive immunosuppressive regimens are mostly recommended. Because there is scarce literature on AHLE management in the paediatric population, we are reporting this case to heighten awareness about effective management. Our case is unique in a way that despite the hyperacute onset, and rapid deterioration with a stormy course in the intensive care unit (ICU), the child survived with good recovery and no neurological sequelae. We conclude that although AHLE is known to be usually fatal, early recognition, aggressive immunosuppression and prompt rehabilitation can increase the odds of survival.
Case presentation
A previously healthy preschool age girl was referred to our paediatric ICU from another city hospital on ventilatory support. The child presented to the city hospital with a 1-day history of projectile vomiting and headache with abrupt onset of neurological symptoms in the form of diminished vision followed by three episodes of generalised tonic seizures lasting 5–10 min with the loss of consciousness. She had no history of antecedent upper respiratory infections, diarrhoea, conjunctivitis, arthralgia or rash. There was no history of recent travel, trauma or vaccinations. The child was ventilated in the outside hospital because of poor Glasgow Coma Scale (GCS), received intravenous antibiotics (ceftriaxone, linezolid) and antivirals (acyclovir), osmotherapy with mannitol and 3% saline and after 10 days of hospital stay with no signs of neurological improvement, she was referred to our tertiary care facility
On admission, the patient was febrile (temperature ~39.4°C); pulse 120 beats/min; blood pressure 106/68 mm Hg and oxygen saturation was 90% on assisted ventilation with no spontaneous respiratory efforts. She was deeply comatose with GCS of 3/15 and absent brainstem reflexes. Her pupils were dilated and non-reactive. She had flaccid quadriplegia with mute deep tendon reflexes and an upgoing plantar response. Cranial nerve examination revealed absent ocular movements, absent corneal, gag and doll’s eye reflex. There were no signs of meningitis and papilledema was absent. Respiratory examination revealed decreased air entry on the left side with coarse crepitations. Abdomen and cardiovascular examinations were within normal limits.
Investigations
Cerebrospinal fluid (CSF) analysis done in the initial hospital on day 2 of illness before initiating antibiotics showed white blood cells—3 cells/mm3 with 98% lymphomononuclear cells, sugar—95 mg/dL, protein—12 mg/dL and brain MRI was reported to be normal as shown in figure 1. Qualitative PCR testing for enteroviruses, adenovirus, human herpesviruses (HHV 6 HHV and 7), herpes simplex viruses (HSV 1 and HSV 2), cytomegalovirus, varicella-zoster virus, Epstein-Barr virus and human parechovirus performed on CSF samples yielded negative results.
The axial T2 and FLAIR images at the level of basal ganglia (A, B) and supraventricular level (C, D) does not show any abnormal signal abnormality. The diffusion-weighted images (E, F) do not reveal any diffusion abnormality. The scan was interpreted as a normal study. FLAIR, fluid-attenuated inversion recovery.

Repeat brain MRI at our hospital (figure 2) revealed symmetrical signal abnormality with restricted diffusion of bilateral striatum, medial thalami, bilateral hippocampi and the superior vermis with associated patchy subcortical fluid-attenuated inversion recovery hyperintensities in bilateral cerebral hemispheres and microhaemorrhages, suggesting a possibility of haemorrhagic acute demyelinating encephalomyelitis. The MR screening of the whole spine was unremarkable. Her electroencephalogram (EEG) was suggestive of diffuse cortical dysfunction.
The axial T2 images (A) shows a subtle hyperintense signal involving the bilateral striatum (white arrows). Abnormal patchy T2 and FLAIR hyperintensities are noted at bilateral frontoparietal subcortical white matter (B, C). The diffusion images (D, E) show focal restriction at the bilateral external capsule. The postcontrast T1 image does not show any abnormal parenchymal or leptomeningeal enhancement (F). FLAIR, fluid-attenuated inversion recovery.

A second MRI performed 30 days later (figure 3) showed resolution of subcortical white matter hyperintensities and thalamic signal alteration with persistent abnormal hyperintensities and restricted diffusion in the bilateral external capsule, fornix and bilateral hippocampus.
Follow-up MRI at an interval of 3 weeks. The axial T2 (A) and FLAIR (B) images show diffuse cerebral atrophy with the resolution of signal changes at the bilateral striatum and bilateral frontoparietal subcortical white matter. The diffusion images (C, D) show T2 shining through at bilateral external capsule without diffusion restriction (white arrows). FLAIR, fluid-attenuated inversion recovery.

The other haematological, biochemical and microbiological investigations of the patient are detailed in table 1.
Haematological, biochemical and microbiological investigations
7June 2020 | 13 June 2020 | 19 July 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AQP-4, aquaporin-4; CRP (hs), C reactive protein (highly sensitive); CSF, cerebrospinal fluid; INR, International normalised ratio; MOG, myelin oligodendrocyte glycoprotein; TLC, total leucocyte count; TPO, thyroid peroxidase; WCC, white cell count. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haemoglobin (105–140 g/L) | 137 | 59 | 99 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TLC (6000–14000/cumm) | 8550 | 17 190 | 13 640 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neutrophils (22%–48%) | 80.6 | 71 | 57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Platelets (1.5–4 lakhs) | 0.42 | 1.69 | 7.53 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sodium (130–145 mmol/L) | 174 | 149 | 134 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Potassium (4.1–5.3 mmol/L) | 1.91 | 3.54 | 4.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Urea (10.8–38.4 mg/dL) | 79 | 110 | 38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Creatinine (0.66–1.09 mg/dL) | 1.16 | 0.44 | 0.28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prothrombin time (11.7 s) | 63.5 | 13.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INR | 5.61 | 1.14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CRP (hs) (<1 mg/L) | 96.1 | 0.693 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bronchial aspirate culture | Acinetobacter baumanii growth | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CSF cytology (0–6 cells/ cumm) | 10 WCC—95% lymphomononuclear | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CSF biochemistry Sugar (40–80 mg/dL) Protein (41–75 mg/dL) |
115 29 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CSF culture | sterile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-MOG and AQP-4 antibodies | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-nuclear antibody | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-TPO antibody | Negative | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Electroencephalogram (10 June 2020) | Low voltage record with no epileptic discharges suggestive of global cerebral dysfunction |
Differential diagnosis
Based on initial clinical presentation, wider differentials including stroke, meningoencephalitis, fulminant demyelinating diseases-like ADEM and its variant AHLE, febrile infection-related epilepsy syndrome (FIRES), neuromyelitis optica (NMO)-spectrum disorders associated with aquaporin autoimmunity and cranial nervous system vasculitides were considered. NMO spectrum disorders were ruled out based on negative anti-aquaporin-4 antibody and myelin oligodendrocyte glycoprotein antibodies. The EEG was not suggestive of FIRES. The results of antinuclear antibodies, inflammatory markers, lipid profile and urine analysis were normal, hence the diagnosis of vasculitis was unlikely. Correlating with the clinical scenario, radiological differential diagnoses included parainfectious demyelinating aetiologies like haemorrhagic ADEM and haemorrhagic meningoencephalitis. CSF analysis showed no evidence of infection and absent meningeal enhancement on neuroimaging excluded infectious causes of meningoencephalitis. The diagnosis of AHLE was made based on the acute fulminant course of the disease and radiological findings but there was no histopathological examination performed to confirm it.
Treatment
At presentation, the child was in respiratory failure with shock, encephalopathy and multiorgan dysfunction syndrome. She was managed with mechanical ventilation, antibiotics, inotropic support and blood products. Pulse therapy with intravenous methylprednisolone (30 mg/kg/day) was initiated, considering the neuroimaging possibility of AHLE. However, there were no signs of clinical improvement even after 5 days of methylprednisolone, hence, therapeutic plasma exchange was initiated. After the first cycle of plasmapheresis, the child showed some improvement like saccadic eye movements and blinking along with spontaneous respiratory efforts and gag reflex. Five cycles of alternate day plasmapheresis were completed. On account of persistent respiratory failure, poor GCS and failure to wean off, tracheostomy was done on day 11 of the PICU stay. Since the child did not show any further clinical improvement, intravenous immunoglobulin (2 g/kg over 2 days) was given on day 14 of stay. The child was continued on oral prednisolone at 1 mg/kg/day. The child was managed with appropriate antibiotics for ventilator-associated pneumonia. She was put off ventilatory support on day 40 with tracheostomy tube in situ. She was then shifted to the ward and aggressive rehabilitation continued. Decannulation was done after 2 months of hospital stay.
Outcome and follow-up
After a month of ICU stay, the patient’s neurological condition improved gradually. The child began communicating with eye gestures and orofacial movements, muscle strength gradually increased to 2/5 in all four limbs, superficial and deep tendon reflexes were regained, and emotional responses appeared. After 2 months of hospitalisation, the child at discharge had improved muscle strength of 3/5 in arms and 2/5 in lower extremities, reactive pupils with no gross cranial nerve deficit and good oral intake. The child regained nearly full strength 3 months after the initial presentation. The girl has no neurological sequelae and has recovered completely after a year of follow-up . On detailed neurological examination, she has muscle strength of 5/5 in all four limbs with normal tone and deep tendon reflexes. Her gait and spine are normal. There is no evidence of spasticity or contractures. She has no trouble performing age-appropriate chores.
Discussion
AHLE is rare in children in comparison to adults. While ADEM is a common disease in children with full recovery, AHLE accounts for only 2% of total ADEM patients with a poor prognosis and nearly 50% mortality. There is a history of antecedent infectious illness of viral or bacterial nature with most cases having upper respiratory tract infection although our case had no prior history of any infection or immunisation.
From the first published report in 1941 till 2021, there have been less than 100 case reports in total and mostly comprising the adult population. Recently, AHLE as post-COVID-19 sequelae has been reported in adults.5 A case report of Weston Hurst syndrome in a child secondary to H1N1 has been reported in past.6 The rare incidence in children, along with a wide range of non-specific clinical manifestations, makes diagnosis challenging and limits the window of opportunity for early therapeutic treatment.
Neuroimaging plays a crucial role in early identification and typically reveals confluent, variable-sized, poorly defined white matter lesions with petechial haemorrhage, significant oedema and mass effect.7 In our case, the first brain MRI done on day 2 days of the illness was reported to be normal. Brain MRI done in our hospital (on day 12 of illness) depicted abnormal signal alteration in bilateral cerebral and thalami involvement with florid microhaemorrhages, which, combined with the clinical history and CSF finding, led us to a definitive diagnosis of AHLE.
Due to lack of understanding of underlying pathophysiology and guidelines defining diagnostic algorithms, many cases are diagnosed retrospectively on basis of histopathological findings. The typical pathological features include neutrophilic infiltration, small vessel necrosis and haemorrhages in a ‘ring and ball’ pattern.8 In our case, a cerebral biopsy was not performed. Only 58% of the patients included in the review by Gronzka et al underwent histopathological examination.4 This shows that roughly 40% of patients did not have a brain biopsy, highlighting the necessity for well-defined standards and indications for cerebral biopsy in fulminant demyelinating diseases.
Given the proposed immune nature of the disease, studies have shown that aggressive treatment with intravenous methylprednisolone, intravenous immunoglobulin, plasmapheresis and mild therapeutic hypothermia is helpful and can be life-saving.9–11 Our patient recovered due to vigorous immunotherapy, which included high-dose steroids, plasma exchange and intravenous immunoglobulins. Prognosis in cases of AHLE is usually guarded. A handful of patients have been reported with near-normal recovery out of proportion to their disease severity and radiological findings.12 Only little is known about favourable prognostic factors in children diagnosed with AHLE. There are a few cases reported in the literature with a mortal course despite early aggressive immunotherapy.3 13 Despite the high mortality rate, our patient made a full recovery with no neurological deficits.
Aggressive therapeutic management is highly advisable without delay to avoid fatal outcomes and achieve complete or near-complete recovery. Early and prompt rehabilitative therapy is fundamental in restoring the maximal attainable function.
Learning points
-
Acute haemorrhagic leukoencephalitis is a fulminant cranial nervous system demyelinating disease with poor prognosis and high mortality.
-
Acute haemorrhagic leukoencephalitis is a rare entity in children, hence high clinical suspicion and prompt neuroimaging can lead to early diagnosis.
-
Our case emphasises the importance of aggressive utilisation of all lines of immune-modulating therapies. Intravenous methylprednisolone followed by five cycles of plasmapheresis followed by intravenous immunoglobulin and oral steroids worked well for our patient.
-
Multidisciplinary team approach involving paediatric intensivist, paediatric neurologist, neuroradiologist, transfusion medicine specialist, physiotherapist, occupational therapist and good nursing staff form the cornerstone of a good recovery.
Ethics statements
Patient consent for publication
Footnotes
-
Contributors HB made substantial contributions to the conception and drafting of the work and revising it critically for important intellectual content and finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. DK made substantial contributions to the conception and drafting of the work and revising it critically for important intellectual content and finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SD made substantial contributions to the drafting of the work and revising it critically for important intellectual content and finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. ST made substantial contributions to the drafting of the work and revising it critically for important intellectual content and finally approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
-
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
-
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
-
Competing interests None declared.
-
Provenance and peer review Not commissioned; externally peer reviewed.
- © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.
References
Use of this content is subject to our disclaimer